Transaction DateRecipientSharesTypePriceValue
8th February 2021Advisors Llc Perceptive1,250,000Open or private purchase$16.00$20,000,000.00
8th February 2021Advisors Llc Perceptive2,941,769Conversion of derivative$0.00
8th February 2021Advisors Llc Perceptive1,770,600Conversion of derivative$0.00
8th February 2021Advisors Llc Perceptive2,857,795Conversion of derivative$0.00
28th January 2021Advisors Llc Perceptive4,219,409Open or private purchase$2.37$9,999,999.33
25th January 2021Advisors Llc Perceptive311,111Open or private purchase$22.50$6,999,997.50
22nd January 2021Advisors Llc Perceptive285,151Open or private sale$8.16$2,326,832.16
22nd January 2021Advisors Llc Perceptive550,000Open or private sale$1.48$814,000.00
22nd January 2021Advisors Llc Perceptive33,849Open or private sale$8.95$302,948.55
21st January 2021Advisors Llc Perceptive674,352Open or private sale$1.68$1,132,911.36
Kadmon Holdings
Kadmon Holdings logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Kadmon Holdings, Inc. is a biopharmaceutical company. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir and Abacavir.


Ticker: KDMN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1557142
Employees: 115
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $170 M (0%)
Inventory, Net: $116 Th (0%)
Assets, Current: $185 M (0%)
Property, Plant and Equipment, Net: $2 M (0%)
Other Assets, Noncurrent: $22 Th (-78%)
Assets: $213 M (0%)
Accounts Payable, Current: $12 M (29%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $30 M (4%)
Liabilities: $50 M (1%)
Common Stock, Value, Issued: $171 Th (6%)
Common Stock, Shares, Issued: $171 M (7%)
Retained Earnings (Accumulated Deficit): $391 M (0%)
Stockholders' Equity (Parent): $163 M (-1%)
Liabilities and Equity: $213 M (0%)
Gross Margin: $336 Th (-94%)
Research and Development: $17 M (-43%)
Operating Income/Loss: $27 M (-37%)
Other Income, net: $232 Th (-98%)
EPS (basic): $0.17 (0%)
EPS (diluted): $0.17 (0%)